Quantamental Technologies LLC purchased a new stake in shares of NxStage Medical, Inc. (NASDAQ:NXTM) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 3,843 shares of the medical device company’s stock, valued at approximately $110,000.
Other institutional investors have also recently made changes to their positions in the company. Tower Research Capital LLC TRC purchased a new position in shares of NxStage Medical during the third quarter valued at $136,000. Rehmann Capital Advisory Group increased its stake in shares of NxStage Medical by 2,689.0% during the third quarter. Rehmann Capital Advisory Group now owns 5,578 shares of the medical device company’s stock valued at $200,000 after buying an additional 5,378 shares during the period. Public Employees Retirement Association of Colorado increased its stake in shares of NxStage Medical by 63.8% during the third quarter. Public Employees Retirement Association of Colorado now owns 8,635 shares of the medical device company’s stock valued at $241,000 after buying an additional 3,362 shares during the period. S. Muoio & CO. LLC purchased a new position in shares of NxStage Medical during the third quarter valued at $284,000. Finally, Janus Henderson Group PLC increased its stake in shares of NxStage Medical by 25.5% during the third quarter. Janus Henderson Group PLC now owns 10,505 shares of the medical device company’s stock valued at $293,000 after buying an additional 2,134 shares during the period. Hedge funds and other institutional investors own 83.57% of the company’s stock.
NXTM opened at $29.25 on Wednesday. NxStage Medical, Inc. has a 1 year low of $22.70 and a 1 year high of $29.33.
NxStage Medical (NASDAQ:NXTM) last posted its earnings results on Wednesday, November 7th. The medical device company reported $0.01 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.02) by $0.03. NxStage Medical had a negative return on equity of 2.50% and a negative net margin of 1.29%. The company had revenue of $108.12 million for the quarter, compared to analyst estimates of $108.07 million. As a group, sell-side analysts anticipate that NxStage Medical, Inc. will post -0.01 EPS for the current year.
Several brokerages have recently commented on NXTM. Zacks Investment Research upgraded NxStage Medical from a “hold” rating to a “buy” rating and set a $33.00 price target on the stock in a research note on Tuesday. BidaskClub lowered NxStage Medical from a “buy” rating to a “hold” rating in a research note on Wednesday, November 28th. Finally, ValuEngine upgraded NxStage Medical from a “hold” rating to a “buy” rating in a research note on Friday, October 12th.
COPYRIGHT VIOLATION NOTICE: This report was published by Enterprise Leader and is the sole property of of Enterprise Leader. If you are viewing this report on another website, it was copied illegally and reposted in violation of US and international trademark & copyright legislation. The original version of this report can be viewed at https://theenterpriseleader.com/2019/02/06/quantamental-technologies-llc-invests-110000-in-nxstage-medical-inc-nxtm.html.
About NxStage Medical
NxStage Medical, Inc, a medical technology company, develops, manufactures, and markets products and services for patients suffering from chronic or acute kidney failure. Its primary product includes the System One, a portable hemodialysis system, which is used primarily for home hemodialysis and a range of dialysis therapies to deliver in the home setting.
Read More: Cash Flow
Want to see what other hedge funds are holding NXTM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for NxStage Medical, Inc. (NASDAQ:NXTM).
Receive News & Ratings for NxStage Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NxStage Medical and related companies with MarketBeat.com's FREE daily email newsletter.